Science & Technology
Development of IFNA2-LNP01 for tumor lung metastases immunotherapy
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43CA287611-01
Award Ceiling
$321K
Award Floor
$321K
Close Date
Apr 30, 2025
Total Funding
$321K
Expected Awards
1
Posted Date
May 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R43CA287611-01
Description
SBIR Phase Phase I award: "Development of IFNA2-LNP01 for tumor lung metastases immunotherapy" awarded to CHEMEDIMMUNE, INC. in AUGUSTA, Georgia. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $320,597. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.